Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.40 |
| ▸ | LPL | P06858 | 12/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226225 | 0.78 | LIPG (0.44) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL16795239 | 0.78 | LIPG (0.45) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL3321140 | 0.77 | ROCK1 (0.55) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL26988116 | 0.77 | F11 (0.44) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL2695426 | 0.77 | LIPG (0.42) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL23984232 | 0.76 | F11 (0.43) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL18197394 | 0.76 | ROCK1 (0.43) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL4815568 | 0.75 | LPL (0.44) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL1284600 | 0.75 | F11 (0.45) | LIPGLPLROCK1F11CA1 | |
| SCHEMBL16831631 | 0.75 | LIPG (0.44) | LIPGLPLROCK1F11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
| EP-3303318-A1 | BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016198400-A1 | BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | LIPG 2052/4885LPL 2955/4885ROCK1 3725/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | LIPG 1103/4885LPL 2702/4885ROCK1 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.